A detailed history of Vanguard Group Inc transactions in Bridge Bio Pharma, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 13,222,126 shares of BBIO stock, worth $335 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
13,222,126
Previous 12,800,294 3.3%
Holding current value
$335 Million
Previous $517 Million 20.88%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$27.35 - $40.45 $11.5 Million - $17.1 Million
421,832 Added 3.3%
13,222,126 $409 Million
Q4 2023

Feb 14, 2024

BUY
$24.02 - $43.89 $36.6 Million - $66.9 Million
1,524,313 Added 13.52%
12,800,294 $517 Million
Q3 2023

Nov 14, 2023

SELL
$16.89 - $35.01 $6.91 Million - $14.3 Million
-409,016 Reduced 3.5%
11,275,981 $297 Million
Q2 2023

Aug 14, 2023

SELL
$13.29 - $18.01 $5.03 Million - $6.81 Million
-378,259 Reduced 3.14%
11,684,997 $201 Million
Q1 2023

May 15, 2023

BUY
$7.17 - $18.55 $10.6 Million - $27.3 Million
1,471,801 Added 13.9%
12,063,256 $200 Million
Q4 2022

Feb 10, 2023

BUY
$6.74 - $11.52 $3.96 Million - $6.76 Million
587,184 Added 5.87%
10,591,455 $80.7 Million
Q3 2022

Nov 14, 2022

BUY
$7.94 - $12.36 $863,347 - $1.34 Million
108,734 Added 1.1%
10,004,271 $99.4 Million
Q2 2022

Aug 12, 2022

BUY
$5.21 - $12.14 $2.46 Million - $5.72 Million
471,425 Added 5.0%
9,895,537 $89.9 Million
Q1 2022

May 13, 2022

BUY
$7.34 - $17.16 $678,428 - $1.59 Million
92,429 Added 0.99%
9,424,112 $95.7 Million
Q4 2021

Feb 14, 2022

SELL
$11.38 - $53.41 $1.18 Million - $5.54 Million
-103,729 Reduced 1.1%
9,331,683 $156 Million
Q3 2021

Nov 12, 2021

SELL
$46.87 - $64.24 $88.8 Million - $122 Million
-1,893,717 Reduced 16.72%
9,435,412 $442 Million
Q2 2021

Aug 13, 2021

BUY
$46.47 - $63.93 $526 Million - $724 Million
11,329,129 New
11,329,129 $691 Million

Others Institutions Holding BBIO

About BridgeBio Pharma, Inc.


  • Ticker BBIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 148,246,000
  • Market Cap $3.76B
  • Description
  • BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...
More about BBIO
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.